Choate recently advised Cyteir Therapeutics in its $29 million Series B preferred stock financing. Cyteir Therapeutics, a leader in the discovery and development of novel therapeutics…
Cyteir Therapeutics’ $29 Million Series B Round Funding
Choate recently advised Cyteir Therapeutics in its $29 million Series B preferred stock financing. Cyteir Therapeutics, a leader in the discovery and development of novel therapeutics…